Leerink Partners Stick to Their Buy Rating for CryoPort Inc By Investing.com – Investing.com

Leerink Partners analyst Puneet Souda maintained a Buy rating on CryoPort (NASDAQ:) Inc on Monday, setting a price target of $75, which is approximately 16.60% above the present share price of $64.32.

Souda expects CryoPort Inc to post earnings per share (EPS) of -$0.16 for the third quarter of 2021.

The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in CryoPort, with an average price target of $78.The analysts price targets range from a high of $80 to a low of $75.

In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $56.19 million and a net profit of -$3.75 million. The company's market cap is $2.96 billion.

According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.2% and a 67.00% success rate.

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See the rest here:

Leerink Partners Stick to Their Buy Rating for CryoPort Inc By Investing.com - Investing.com